Market Place
Sourcing Support
PaxMedica Files Nasdaq Delisting Appeal, Prepares For FDA PAX-101 Meeting
15 May 2024 //
GLOBENEWSWIRE
PaxMedica Provides Update, Advances PAX-101 Regulatory Strategy
07 May 2024 //
GLOBENEWSWIRE
PaxMedica To Provide Immediate PAX-101 IV Suramin Access
23 Apr 2024 //
GLOBENEWSWIRE
PaxMedica Receives Emergency IV Suramin Request from African Health Ministry
16 Apr 2024 //
GLOBENEWSWIRE
PaxMedica PAX-101 Milestone, Update on Potential NDA Filing
11 Apr 2024 //
GLOBENEWSWIRE
PaxMedica Company Presentation Highlighting Innovations in Autism Disorder
13 Mar 2024 //
GLOBENEWSWIRE
PaxMedica Announces Closing of $7.0 Million Public Offering
22 Nov 2023 //
ACCESSWIRE
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting
17 Nov 2023 //
GLOBENEWSWIRE
PaxMedica Announces Third Quarter 2023 Financial Results and Business Update
15 Nov 2023 //
ACCESSWIRE
PaxMedica Announces Publication of Autism Spectrum Disorder Ph 2 Study Results
07 Nov 2023 //
ACCESSWIRE
PaxMedica Engages Bourne Partners to Explore Future Monetization of PRV
02 Nov 2023 //
GLOBENEWSWIRE
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences
31 Oct 2023 //
GLOBENEWSWIRE
PaxMedica Announces 1-for-17 Reverse Stock Split
30 Oct 2023 //
GLOBENEWSWIRE
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Trial Data
26 Oct 2023 //
ACCESSWIRE
PaxMedica`s Research on Low Dose Suramin Accepted for Publication
26 Oct 2023 //
GLOBENEWSWIRE
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation`s Symposia 2023
10 Oct 2023 //
ACCESSWIRE
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Conference
30 Aug 2023 //
GLOBENEWSWIRE
PaxMedica Appoints David Hough M.D. as Chief Medical Officer
16 Aug 2023 //
GLOBENEWSWIRE
PaxMedica Announces Second Quarter 2023 Financial Results and Business Update
09 Aug 2023 //
GLOBENEWSWIRE
PaxMedica to Join Fireside Chat Following Results from PAX-HAT-301 Study
08 Aug 2023 //
ACCESSWIRE
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101
06 Jul 2023 //
GLOBENEWSWIRE
PaxMedica Comments on Common Stock Volatility
22 Jun 2023 //
GLOBENEWSWIRE
PaxMedica CEO Interviewed by The BRAIN Foundation
20 Jun 2023 //
GLOBENEWSWIRE
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder
14 Jun 2023 //
GLOBENEWSWIRE
PaxMedica Enters Research Collaboration Agreement With PoloMar Health
08 Jun 2023 //
GLOBENEWSWIRE
PaxMedica Completes HAT-301 Registrational Trial for PAX-101
01 Jun 2023 //
GLOBENEWSWIRE
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301
15 May 2023 //
GLOBENEWSWIRE
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial PO
19 Apr 2023 //
GLOBENEWSWIRE
PaxMedica Reports Fourth Quarter 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
PaxMedica Holds Meeting of Scientific Advisory Board
20 Mar 2023 //
GLOBENEWSWIRE
PaxMedica Releases 2022 Shareholder Letter
15 Feb 2023 //
GLOBENEWSWIRE
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
03 Feb 2023 //
GLOBENEWSWIRE
PaxMedica to Present at Jan 26th Investor Summit Microcap Event
20 Jan 2023 //
GLOBENEWSWIRE
PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
14 Dec 2022 //
GLOBENEWSWIRE
PaxMedica to Present at the Benchmark Company’s Conference
22 Nov 2022 //
GLOBENEWSWIRE
PaxMedica surges after financing; Marinus makes China development and sales pact
19 Nov 2022 //
ENDPTS
PaxMedica, Enters Into Committed Equity Investment Agreement for up to $20 M
17 Nov 2022 //
GLOBENEWSWIRE
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer
24 Oct 2022 //
GLOBENEWSWIRE
PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento
03 Oct 2022 //
GLOBENEWSWIRE
PaxMedica, Inc. Announces Pricing of Initial Public Offering
26 Aug 2022 //
GLOBENEWSWIRE
Small neurology biotech announces prices its $8M IPO
26 Aug 2022 //
ENDPTS
SAHPRA grants approval to begin trial of PaxMedica’s long Covid-19 therapy
10 Jan 2022 //
CLINICALTRIALSARENA
PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in COVID-19 Syndrome
07 Jan 2022 //
PRNEWSWIRE
IV suramin may be a promising autism treatment, shows Phase II study
29 Oct 2021 //
EUROPEANPHARMACEUTICALREVIEW
